(56 days)
Not Found
Not Found
No
The device description and performance studies describe a standard enzyme immunoassay (EIA) kit, which relies on chemical reactions and colorimetric measurements, not AI/ML algorithms for analysis or interpretation. There are no mentions of AI, ML, or related concepts in the provided text.
No
The device aids in diagnosis and evaluates risk, but it does not treat or prevent a medical condition directly.
Yes
The "Intended Use / Indications for Use" section explicitly states that the kit is designed "to aid in the diagnosis of antiphospholipid syndrome (APS)."
No
The device is an enzyme immunoassay kit, which is a laboratory test involving physical reagents and a microplate, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "semiquantitative and qualitative determination of IgG antibodies against cardiolipin in serum or plasma to aid in the diagnosis of antiphospholipid syndrome (APS) and to evaluate the thrombotic risk in patients with systemic lupus erythematosus (SLE)." This involves testing samples taken from the human body (serum or plasma) in vitro (outside the body) to provide information for diagnosis and risk assessment.
- Device Description: The description details an "indirect noncompetitive enzyme immunoassay" performed on "human serum or plasma." This further confirms that the testing is done on biological samples outside of the living organism.
These are key characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Varelisa Cardiolipin IgG Antibodies EIA kit is designed for the semiquantitative and qualitative determination of IgG antibodies against cardiolipin in serum or plasma to aid in the diagnosis of antiphospholipid syndrome (APS) and to evaluate the thrombotic risk in patients with systemic lupus erythematosus (SLE).
Product codes (comma separated list FDA assigned to the subject device)
82MID
Device Description
The Varelisa Cardiolipin IgG Antibodies is an indirect noncompetitive enzyme immunoassay for the semiquantitative and qualitative determination of IgG antibodies against cardiolipin in serum or plasma.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The comparability of the new and the old version Varelisa Cardiolipin IgG Antibodies is supported by a data set including
- . results obtained within a comparison study analyzing positive, equivocal and negative sera
- . results obtained for externally defined Calibrators and Quality Assessment sera
- results obtained for samples from apparently healthy subjects (normal population) .
The data show that the assay performs as expected from the medical literature. Differing results are probably due to the changed blocking procedure.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.5660 Multiple autoantibodies immunological test system.
(a)
Identification. A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).(b)
Classification. Class II (performance standards).
0
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS 9.
This summary of safety and effectiveness information is being submitted in accordance with the requirements of The Safety Medical Devices Act of 1990 (SMDA 1990) and 21 CFR Part 807.92.
Assigned 510(k) Number: K020752
Date of Summary Preparation:
February 11, 2002
Munzingerstrasse 7
D-79111 Freiburg, Germany
Distributor:
Pharmacia Diagnostics Division, US Operation 7425-248-1 7000 Portage Road Kalamazoo, MI 49001
Pharmacia Deutschland GmbH, Diagnostics Division
Manufacturer:
Company Contact Person:
Michael Linss Manager, Regulatory Affairs Pharmacia Deutschland GmbH Diagnostics Division Munzingerstrasse 7 Freiburg, Germany Telephone +49-761-47-805-310 Facsimile +49-761-47-805-120
Device Name:
Varelisa® Cardiolipin IgG Antibodies
Common Name:
Cardiolipin autoantibody immunological test system
Classification:
| Product Name | Product Code | Class | CFR |
|---|---|---|---|
| Varelisa® Cardiolipin IgG Antibodies | 82MID | II | 866.5560 |
1
Substantial Equivalence to:
Varelisa® Cardiolipin (IgG) Antibodies
Intended Use Statement
The Varelisa Cardiolipin IgG Antibodies EIA kit is designed for the semiquantitative and qualitative determination of IgG antibodies against cardiolipin in serum or plasma to aid in the diagnosis of antiphospholipid syndrome (APS) and to evaluate the thrombotic risk in patients with systemic lupus erythematosus (SLE).
General Description of the Device
The Varelisa Cardiolipin IgG Antibodies is an indirect noncompetitive enzyme immunoassay for the semiquantitative and qualitative determination of IgG antibodies against cardiolipin in serum or plasma.
Anti-cardiolipin antibodies (aCL) belong to the group of anti-phospholipid antibodies (aPL). aCL are considered to be of significant diagnostic relevance, as a correlation has been found between these antibodies and a tendency towards thromboses. This results in an increased incidence of venous/arterial thromboses (including apoplexy), thrombocytopenia, livedo reticularis, habitual abortion and neurological manifestations in aCL/LA-positive patients. Elevated levels of aCL may also be found in patients with cerebrovascular insufficiency or myocardial infarction. aPL play a direct role in the pathogenesis of APS.
Varelisa® Cardiolipin IgG Antibodies Test Principle
Varelisa Cardiolipin IgG Antibodies is an indirect noncompetitive enzyme immunoassay for the semiquantitative and qualitative determination of cardiolipin IgG antibodies in human serum or plasma. The wells of a microplate are coated with bovine cardiolipin antigen. Antibodies specific for cardiolipin present in the patient sample bind to the antigen.
In a second step an enzyme labeled second antibody (Conjugate) binds to the antigenantibody complex which leads to the formation of an enzyme labeled antigen-antibody sandwich complex.
The enzyme labeled antigen-antibody complex converts the added substrate to form a colored solution. The rate of color formation from the chromogen is a function of the amount of Conjugate complexed with the bound antibody and thus is proportional to the initial concentration of the respective antibodies in the patient sample.
2
Device Comparison
Varelisa Cardiolipin (IgG) Antibodies (the original/predicate device) and Varelisa Cardiolipin IgG Antibodies (the new/modified device) both are indirect noncompetitive enzyme immunoassays for semiquantitative and qualitative determination of IgG antibodies against Cardiolipin in serum or plasma.
Based on currently available data from the literature the measuring of these antibodies not only provides aid in the evaluation of the thrombotic risk in patients with systemic lupus erythematosus, but also aids in the diagnosis of the antiphospholipid syndrome (APS). Thus the intended use of Varelisa Cardiolipin IgG Antibodies was adapted to the current state of scientific knowledge.
The essential differences between both assays are the new choice of antigen supplier and a changed blocking procedure.
Important common features between old and new version are the nature of the antigen determining the specificity of the assay, Bovine Cardiolipin, and the presence of $2glycoprotein I in the blocking buffer.
Laboratory equivalence
The comparability of the new and the old version Varelisa Cardiolipin IgG Antibodies is supported by a data set including
- . results obtained within a comparison study analyzing positive, equivocal and negative sera
- . results obtained for externally defined Calibrators and Quality Assessment sera
- results obtained for samples from apparently healthy subjects (normal population) .
The data show that the assay performs as expected from the medical literature. Differing results are probably due to the changed blocking procedure.
In summary, all available data support that the new/modified device, Varelisa Cardiolipin IgG Antibodies Assay is substantially equivalent to the predicate/original device, Varelisa Cardiolipin (IgG) Antibodies Assay, and that the new/modified device performs according to state-of-the-art expectations.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of the department's name arranged in a circular fashion around a symbol. The symbol is a stylized representation of a human figure, with three overlapping profiles suggesting a sense of community and support. The logo is presented in black and white.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Michael Linss, Ph.D. Manager, Regulatory Affairs Pharmacia Deutschland GmbH Diagnostics Division Munzinger Strasse 7 Freiburg GERMANY
MAY 0 2 2002
Re: K020752
Trade/Device Name: Varelisa® Cardiolipin IgG Antibodies Regulation Number: 21 CFR 866.5660 Regulation Name: Multiple Autoantibodies Immunological Test Sytem Regulatory Class: II Product Code: MID Dated: March 6, 2002 Received: March 7, 2002
Dear Dr. Linss:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket This letter will and in you disubstantial equivalence of your device to a legally marketed nouticate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and If you desire specific dain vitro diagnostic devices), please contact the Office of Compliance at additionally 607.10 101 ====================================================================================================================================================== (301) 594-1566. entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small monitation on your respond and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Putman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Varelisa® Cardiolipin IgG Antibodies- Device Modification 510(k) Submission Section 1. Indications for Use Statement
Kogo752 510(k) Number:
Device Name: Varelisa® Cardiolipin IgG Antibodies
Intended Use Statement
The Varelisa Cardiolipin IgG Antibodies EIA kit is designed for the semiquantitative and qualitative determination of IgG antibodies against cardiolipin in serum or plasma to aid in the diagnosis of antiphospholipid syndrome (APS) and to evaluate the thrombotic risk in patients with systemic lupus erythematosus (SLE).
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use v
OR
Over-The-Counter Use
(Per 21 CFR 801.109)
Dorothea Menon
(Division Sign-Off Division of Clinical Lat 510(k) Number
CL-G1.doc